Imugene Ltd: Half Yearly Report and Accounts

ASXFeb 27 18:00 ET · Announcements

Why GQG, Imugene, Mirvac, and Temple & Webster Shares Are Pushing Higher

The Motley FoolFeb 13 21:02 ET

Imugene Therapy Achieves Two Complete Responses in Patients With Blood Cancer, Shares Rise Past 8%

MT NewswiresFeb 13 20:41 ET

Which ASX 200 Healthcare Share Will Pay the Best Dividend Yield in 2025?

The Motley FoolFeb 5 21:53 ET

Imugene Receives A$11.7 Million R&D Tax Refund

Investing.com Jan 12 17:16 ET

Imugene Receives A$11.7 Million R&D Tax Refund | ASX:IMU, OTC:IUGNF

Proactive InvestorsJan 12 17:16 ET

Imugene Ltd: Imugene Receives $11.7m R&D Tax Refund

ASXJan 9 21:31 ET · Announcements

Why Cettire, Gold Road, Imugene, and Paladin Energy Shares Are Racing Higher

The Motley FoolJan 2 20:31 ET

First Aussie Doses Bring Imugene Major Step Closer to 'Quicker, Cheaper' Non-Hodgkin's Lymphoma Care

The Market HeraldJan 2 19:56 ET

Guess Which ASX Small Cap Stock Is Jumping on 'Significant Milestone'

The Motley FoolJan 2 19:28 ET

Imugene Says First Australian Patient Dosed in Lymphoma Trial

MT NewswiresJan 2 18:19 ET

ASX Preview: Australian Shares to Open Lower Amid Wall Street Losses

MT NewswiresJan 2 17:40 ET

Imugene Receives Substantial Capital Injection; Extends Cash Runway to End of 2025 in Support of Ongoing Trials

Investing.com Dec 23, 2024 17:10 ET

Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue

MT NewswiresDec 23, 2024 16:58 ET

Imugene to Receive A$11 Million R&D Tax Refund for FY23 | ASX:IMU, OTC:IUGNF

Proactive InvestorsDec 18, 2024 17:12 ET

6 ASX Shares Down 50%+ in 2024. Are They Cheap?

The Motley FoolDec 2, 2024 23:59 ET

Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial

MT NewswiresNov 10, 2024 20:42 ET

Five at Five AU: ASX to End Week on a High Note | ASX:IMU, OTC:IUGNF

Proactive InvestorsNov 7, 2024 23:31 ET

Why Imugene, Neuren, Sigma, and Smartgroup Shares Are Charging Higher

The Motley FoolNov 7, 2024 21:13 ET

Imugene Opens First Australian Site for Azer-cel Clinical Trial Targeting Lymphoma | ASX:IMU, OTC:IUGNF

Proactive InvestorsNov 7, 2024 19:48 ET